- Stocks
- Pharma & Healthcare
- Narayana Hrudayalaya
Narayana Hrudayalaya share price
NSE: NHPharma & HealthcareMedical Care Facilities
Narayana Hrudayalaya at a glance
Narayana Hrudayalaya (NSE: NH) closed at ₹1,691.90 on 22 Oct 2026, down 2.21% on the day. With a market capitalisation of ₹34,602 Cr, it ranks 245th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
At its last close the stock traded at 42.4× trailing earnings, against a return on equity of 17.8% in FY26. Over the past year the share price has fallen 2.8%. Its 52-week range is ₹1,589.00 (2 Apr 2026) to ₹2,093.30 (17 Nov 2025); the last close is 19.2% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹2,684 Cr (+78.0% year on year) and net profit ₹209 Cr (+6.1%), on a consolidated basis. Promoters held 63.27% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹34,602 CrRank 245 on NSE
- P/E (trailing)
- 42.4×
- Price to book
- 7.23×FY26
- EPS (TTM)
- ₹40.18to Q1 FY27
- ROE
- 17.8%FY26
- ROCE
- 11.9%FY26
- Debt to equity
- 1.07FY26
- Net profit margin
- 10.2%FY26
- Book value / share
- ₹222.02FY26
- 52-week high
- ₹2,093.3017 Nov 2025
- 52-week low
- ₹1,589.002 Apr 2026
- 1-year return
- −2.8%
- RSI (14-day)
- 36.9
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −2.21% | +0.7% | −10.8% | −14.2% | −2.8% |
Narayana Hrudayalaya quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,400 Cr | ₹1,367 Cr | ₹1,475 Cr | ₹1,507 Cr | ₹1,644 Cr | ₹2,151 Cr | ₹2,594 Cr | ₹2,684 Cr |
| Revenue YoY | +7.3% | +13.5% | +15.3% | +12.4% | +17.4% | +57.4% | +75.8% | +78.0% |
| Net profit | ₹199 Cr | ₹193 Cr | ₹197 Cr | ₹197 Cr | ₹259 Cr | ₹127 Cr | ₹226 Cr | ₹209 Cr |
| Net profit YoY | −12.3% | +2.6% | +3.4% | −2.2% | +30.0% | −34.3% | +14.5% | +6.1% |
| Net margin | 14.2% | 14.1% | 13.4% | 13.1% | 15.7% | 5.9% | 8.7% | 7.8% |
| EPS | ₹9.78 | ₹9.50 | ₹9.71 | ₹9.68 | ₹12.72 | ₹6.24 | ₹11.02 | ₹10.20 |
Narayana Hrudayalaya financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹2,582 Cr | ₹3,701 Cr | ₹4,525 Cr | ₹5,018 Cr | ₹5,483 Cr | — |
| Operating profit | −₹49 Cr | ₹438 Cr | ₹752 Cr | ₹889 Cr | ₹944 Cr | — |
| Net profit | −₹7 Cr | ₹351 Cr | ₹607 Cr | ₹790 Cr | ₹791 Cr | — |
| EPS (₹) | −₹1.00 | ₹17.00 | ₹30.00 | ₹39.00 | ₹39.00 | — |
| Cash from operations | ₹309 Cr | ₹485 Cr | ₹1,085 Cr | ₹1,067 Cr | ₹986 Cr | — |
| Total debt | ₹504 Cr | ₹432 Cr | ₹626 Cr | ₹1,195 Cr | ₹1,966 Cr | ₹4,667 Cr |
| Shareholders' equity | ₹1,120 Cr | ₹1,489 Cr | ₹2,131 Cr | ₹2,884 Cr | ₹3,624 Cr | ₹4,537 Cr |
Narayana Hrudayalaya shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 63.85% | 63.85% | 63.85% | 63.27% | 63.27% | 63.27% |
| Foreign institutions | 9.66% | 10.46% | 10.49% | 11.10% | 9.98% | 9.40% |
| Domestic institutions | 8.52% | 8.09% | 7.76% | 7.91% | 9.15% | 9.06% |
| Non-institutions | 17.35% | 16.98% | 17.29% | 17.10% | 16.98% | 17.65% |
Narayana Hrudayalaya vs peers
The listed Pharma & Healthcare companies nearest to Narayana Hrudayalaya by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| AJANTPHARMAjanta Pharma | ₹3,260.00 | 0.00% | +36.1% | ₹40,861 Cr | 38.6 | 23.3% |
| NHNarayana Hrudayalaya | ₹1,691.90 | −2.21% | −2.8% | ₹34,602 Cr | 42.4 | 17.8% |
| EMCUREEmcure Pharmaceuticals | ₹1,759.20 | +0.09% | +31.6% | ₹33,812 Cr | 145.1 | 18.7% |
| MEDANTAGlobal Health | ₹1,215.10 | −1.65% | −10.1% | ₹32,216 Cr | 58.9 | 14.0% |
| LALPATHLABDr. Lal Path Labs | ₹1,838.50 | +0.46% | +16.3% | ₹30,907 Cr | 58 | 20.1% |
| WOCKPHARMAWockhardt | ₹1,889.60 | +0.46% | +38.2% | ₹30,150 Cr | 144.8 | 4.3% |
| SAILIFESai Life Sciences | ₹1,396.80 | −0.06% | +63.2% | ₹29,633 Cr | 85.1 | 8.0% |
Ask anything about Narayana Hrudayalaya
Pivot answers on the live chart with evidence you can check, and tests strategies against NH's own history. Try: “Why has NH moved over the last three months?” · “Backtest a 50-day moving-average crossover on NH over five years” · “Compare NH with AJANTPHARM on margins and valuation”
Frequently asked questions about Narayana Hrudayalaya
What is the share price of Narayana Hrudayalaya today?
Narayana Hrudayalaya (NSE: NH) last closed at ₹1,691.90 on 22 Oct 2026. Its 52-week high is ₹2,093.30 and its 52-week low is ₹1,589.00.
What is the market cap of Narayana Hrudayalaya?
Narayana Hrudayalaya's market capitalisation is ₹34,602 Cr (₹34,602 Cr) at the 22 Oct 2026 close, ranking 245th among the NSE companies Pivot tracks.
What is the P/E ratio of Narayana Hrudayalaya?
Narayana Hrudayalaya trades at a trailing P/E of 42.4. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 85.1.
What is the ROE and ROCE of Narayana Hrudayalaya?
Return on equity was 17.8% in FY26 and return on capital employed was 11.9% in FY26 (consolidated figures).
Is Narayana Hrudayalaya a debt-free company?
No. Narayana Hrudayalaya's debt-to-equity ratio was 1.07 in FY26, with total debt of ₹4,667 Cr.
What were Narayana Hrudayalaya's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Narayana Hrudayalaya reported revenue of ₹2,684 Cr, +78.0% year on year, and net profit of ₹209 Cr, +6.1% year on year.
How has Narayana Hrudayalaya stock performed over the last year?
Narayana Hrudayalaya's share price has fallen 2.8% over the past year, −14.2% over three months and −10.8% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Narayana Hrudayalaya?
As of 30 Jun 2026: promoters 63.27%, foreign institutions 9.40%, domestic institutions 9.06%, non-institutions 17.65%.
Who are Narayana Hrudayalaya's competitors?
The listed Pharma & Healthcare companies closest to Narayana Hrudayalaya by market cap are Ajanta Pharma, Emcure Pharmaceuticals, Global Health, Dr. Lal Path Labs, Wockhardt and Sai Life Sciences.
Is Narayana Hrudayalaya a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Narayana Hrudayalaya's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NH against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with N · all NSE stocks · this page as text